ALSF Childhood Cancer Research Grants
With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,500 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
Project Title | Institution / Principal Investigator(s) | Grant Type | Year | State |
---|---|---|---|---|
Optimizing TCRαβ+/CD19+-depleted haploidentical HSCT for ALL using donor-derived genome-edited CAR T cells | Stanford University School of Medicine / Alice Bertaina, MD/PhD | Reach Grants | 2019 | California |
Stapled Peptide PROTAC: A 3-in-1 Treatment for Pediatric Solid Tumors | Dana-Farber Cancer Institute / Loren Walensky, MD/PhD | Reach Grants | 2021 | Massachusetts |
Multivalent Nanomedicine to Treat High-Risk Pediatric Solid Tumors | Children’s Hospital of Philadelphia / Garrett Brodeur, MD | Reach Grants | 2019 | Pennsylvania |
DNA Methylation Inhibitor Therapy for Testicular Germ Cell Tumors | University of Illinois, Urbana-Champaign / Michael Spinella, Ph.D. | Reach Grants | 2014 | Illinois |
Therapeutic Targeting of PGBD5-induced DNA Repair Dependency in Pediatric Solid Tumors | Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD/PhD | Reach Grants | 2017 | New York |
Identifying Novel Therapeutic Combinations with 131I-MIBG to Treat Relapsed and Refractory Neuroblastoma | The Regents of the University of California San Francisco / William Clay Gustafson, M.D., Ph.D. | Reach Grants | 2014 | California |
Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children | Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD/PhD | Reach Grants | 2018 | Washington |
Therapeutic Reactivation of p53 to Overcome Apoptotic Resistance in Pediatric Leukemia | Dana-Farber Cancer Institute / Loren Walensky, MD, PhD & Kimberly Stegmaier, MD | Reach Grants | 2015 | Massachusetts |
Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma | Duke University Medical Center / Gerard Blobe, MD, PhD | Reach Grants | 2013 | North Carolina |
Mechanistic and Therapeutic Development of ATM as a Tumor Cell Selective Target for Radiosensitization in H3K27M DMG | The Regents of the University of Michigan / Meredith Morgan, PhD & Daniel Wahl, MD/PhD | Reach Grants | 2022 | Michigan |